(R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl 4-methyl-2-oxopent-3-enoate

ID: ALA5184698

Chembl Id: CHEMBL5184698

PubChem CID: 168283775

Max Phase: Preclinical

Molecular Formula: C22H22O7

Molecular Weight: 398.41

Names and Identifiers

Canonical SMILES:  CC(C)=CC[C@@H](OC(=O)C(=O)C=C(C)C)C1=CC(=O)c2c(O)ccc(O)c2C1=O

Standard InChI:  InChI=1S/C22H22O7/c1-11(2)5-8-18(29-22(28)17(26)9-12(3)4)13-10-16(25)19-14(23)6-7-15(24)20(19)21(13)27/h5-7,9-10,18,23-24H,8H2,1-4H3/t18-/m1/s1

Standard InChI Key:  RXWAFPNBARJIIJ-GOSISDBHSA-N

Alternative Forms

1. Parent:

   

   ALA5184698

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 398.41

Molecular Weight (Monoisotopic): 398.1366

AlogP: 3.21

#Rotatable Bonds: 6

Polar Surface Area: 117.97

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.50

CX Basic pKa: ┄

CX LogP: 5.36

CX LogD: 5.33

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.25

Np Likeness Score: 1.92

References

1. Valipour M..  (2022)  Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.,  235  [PMID:35367708] [10.1016/j.ejmech.2022.114314]

Source

Source(1):

• Scientific Literature